Number 805 • July 2019

# Temporary Benefit added to the Alberta Drug Benefit List (ADBL)

Due to the unavailability of Accel-Pioglitazone 15 mg Tablet (DIN 02303442), manufactured by Accel Pharma Inc., Apo-Pioglitazone 15 mg Tablet (DIN 02302942), manufactured by Apotex Inc., will be considered as a temporary benefit for the Alberta Drug Benefit List (ADBL).

As of July 9, 2019, all claims for Apo-Pioglitazone 15 mg Tablet (DIN 02302942) will be adjudicated to the price published in the most recent Alberta Blue Cross Drug Price List (ABCDPL) until further notice. The ABCDPL is available online at https://www.ab.bluecross.ca/providers/pharmacy-price-files.php.

If this situation continues to be a long-term matter then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the ADBL to remain as a benefit.

## Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Pharmascience Inc. and Sandoz Canada Inc. that the shortages of pms-Diclofenac-SR 75 mg Sustained-Release Tablet (DIN 02231504) and Sandoz Diclofenac SR 75 mg Extended-Release Tablet (DIN 02261901) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 15, 2019**.

## **DICLOFENAC SODIUM**

## **75 MG SUSTAINED-RELEASE TABLET**

00002162814	APO-DICLO SR	APX	\$ 0.2320
00002231504	PMS-DICLOFENAC-SR	PMS	\$ 0.2320
00002261901	SANDOZ DICLOFENAC SR	SDZ	\$ 0.2320
00002158582	TEVA-DICLOFENAC SR	TEV	\$ 0.2320
00000782459	VOLTAREN SR	NOV	\$ 1.2437



Number 805 • July 2019

Alberta Blue Cross has been advised by Pharmascience Inc. and Sandoz Canada Inc. that the shortages of pms-Diclofenac-SR 100 mg Sustained-Release Tablet (DIN 02091194) and Sandoz Diclofenac SR 100 mg Extended-Release Tablet (DIN 02261944) respectively have been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **August 15, 2019**.

### **DICLOFENAC SODIUM**

#### 100 MG SUSTAINED-RELEASE TABLET

00002091194	APO-DICLO SR	APX	\$ 0.4048
00002231505	PMS-DICLOFENAC-SR	PMS	\$ 0.4048
00002261944	SANDOZ DICLOFENAC SR	SDZ	\$ 0.4048
00000590827	VOLTAREN SR	NOV	\$ 1.7729

# When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



